Total costs and QALYs for each strategy and incremental results were presented.
Incremental QALYs for treatment with liraglutide 1.2mg compared with glimepiride were 0.32 and compared with sitagliptin were 0.19. Incremental costs for liraglutide 1.2mg compared with glimepiride were £3,003 and compared with sitagliptin were £1,842.
Incremental QALYs for treatment with liraglutide 1.8mg compared with glimepiride were 0.28 and compared with sitagliptin were 0.31. Incremental costs for liraglutide 1.8mg compared with glimepiride were £4,688 and compared with sitagliptin were £3,224.
The incremental cost-effectiveness ratio (ICER) for liraglutide 1.2mg compared with glimepiride was £9,449 per QALY gained and compared with sitagliptin was £9,851 per QALY gained.
The ICER for liraglutide 1.8 mg was £16,501 per QALY gained compared with glimepiride and £10,465 per QALY gained compared with sitagliptin.
Sensitivity analysis showed that systolic blood pressure, weight and cholesterol were the key drivers of cost-effectiveness in the liraglutide versus glimepiride comparison, with a relatively small contribution from HbA1c. HbA1c and weight were the key drivers of cost-effectiveness in the liraglutide versus sitagliptin comparison, with only small effects from systolic blood pressure and cholesterol.